Tech Center 1600 • Art Units: 1631 1633 1638 1654 1656
This examiner grants 74% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18066149 | GENE THERAPY FOR AMYOTROPHIC LATERAL SCLEROSIS AND OTHER SPINAL CORD DISORDERS | Non-Final OA | Genzyme Corporation |
| 18175790 | METHODS AND SYSTEMS FOR REAL-TIME, CONTINUOUS PRODUCTION OF NON-VIRAL CARRIER NUCLEIC ACID PARTICLES | Non-Final OA | CORNING INCORPORATED |
| 18573858 | METHODS AND COMPOSITIONS FOR REMOTE CONTROL OF T CELL THERAPIES BY THERMAL TARGETING | Non-Final OA | GEORGIA TECH RESEARCH CORPORATION |
| 18049405 | Transdermal Optogenetic Peripheral Nerve Stimulation | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18018552 | UNIVERSAL ANTIGEN-SPECIFIC T CELL BANKS AND METHODS OF MAKING AND USING THE SAME THERAPEUTICALLY | Non-Final OA | Baylor College of Medicine |
| 17913482 | NON-VIRAL DNA VECTORS AND USES THEREOF FOR EXPRESSING GAUCHER THERAPEUTICS | Non-Final OA | Generation Bio Co. |
| 18304843 | Use of CD2/5/7 Knock-Out Anti-CD2/5/7 Chimeric Antigen Receptor T cells Against T Cell Lymphomas and Leukemias | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18325332 | Systemic Delivery of Polypeptides | Non-Final OA | The General Hospital Corporation |
| 18311367 | SELF-REGULATING AAV VECTORS FOR SAFE EXPRESSION OF MECP2 IN RETT SYNDROME | Non-Final OA | University of Massachusetts |
| 18297808 | USE OF NOVEL MIRNA-BINDING SITE CASSETTES FOR ANTIGEN-PRESENTING CELL DETARGETING OF TRANSGENE EXPRESSION BY RAAV GENE THERAPY | Non-Final OA | University of Massachusetts |
| 18015426 | METHOD OF TREATMENT OF CONGENITAL MYASTHENIC SYNDROME USING DOK7 GENE OR POLYPEPTIDE | Non-Final OA | Oxford University Innovation Limited |
| 18031413 | Gelatin Microparticles Containing Nutrients for Cell Culture Therein, Preparation Method Therefor, and Use Thereof | Final Rejection | CJ CHEILJEDANG CORPORATION |
| 17843896 | THYMIDINE KINASE GENE | Final Rejection | Genvivo, Inc. |
| 18187884 | COMPOSITIONS AND METHODS FOR TREATMENT OF NETHERTON SYNDROME | Non-Final OA | Krystal Biotech, Inc. |
| 18209766 | Conjugated Polymeric Particle and Method of Making Same | Non-Final OA | LIFE TECHNOLOGIES CORPORATION |
| 18274649 | Surface Modified Red Blood Cells And Methods Of Generating The Same | Non-Final OA | CITY UNIVERSITY OF HONG KONG |
| 17829087 | RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTES | Final Rejection | Iovance Biotherapeutics Inc. |
| 17924456 | LNP COMPOSITIONS COMPRISING AN MRNA THERAPEUTIC AND AN EFFECTOR MOLECULE | Final Rejection | ModernaTX, Inc. |
| 18568456 | TOBAMOVIRUS PSEUDOVIRIONS FOR STABILISING SINGLE STRANDED RNA | Non-Final OA | University of Cape Town |
| 18573114 | ANTI-CRISPR CONSTRUCT AND ITS USE TO COUNTERACT A CRISPR-BASED GENE-DRIVE IN AN ARTHROPOD POPULATION | Non-Final OA | Polo D’Innovazione di Genomica Genetica e Biologia SRL |
| 18161806 | COMPOSITIONS AND METHODS FOR TREATING CEP290 ASSOCIATED DISEASE | Non-Final OA | EDITAS MEDICINE, INC. |
| 18564869 | DENTAL COMPOSITION AND DENTINE CULTURING METHOD | Non-Final OA | AIR WATER INC. |
| 18327110 | ENGINEERED CELLS AND METHODS OF USE | Non-Final OA | THE SCRIPPS RESEARCH INSTITUTE |
| 18472176 | MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA | Non-Final OA | Astellas Institute for Regenerative Medicine |
| 17328966 | METHOD OF TREATMENT | Final Rejection | MONASH UNIVERSITY |
| 18557146 | THERAPEUTIC DRUG FOR MYOTONIC DYSTROPHY TYPE 1 | Non-Final OA | EDITFORCE, INC. |
| 18308457 | SYNTHETIC DNA VECTORS AND METHODS OF USE | Non-Final OA | Aldevron, LLC |
| 18185273 | MICROFLUIDIC LASER-ACTIVATED INTRACELLULAR DELIVERY SYSTEMS AND METHODS | Non-Final OA | Cellino Biotech, Inc. |
| 18340016 | OLIGONUCLEOTIDES TARGETING XBP1 | Non-Final OA | Roche Innovation Center Copenhagen A/S |
| 18329015 | Mannose-Based mRNA Targeted Delivery System and Use Thereof | Non-Final OA | Shenzhen Rhegen Biotechnology Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy